New Journey! Bellen Chemistry Co., Ltd.'s Initial Public Offering Approved by the Listing Committee of the Shenzhen Stock Exchange.

The announcement of the 85th review meeting of the Shenzhen Stock Exchange listing review committee in 2023 reveals that the initial public offering (IPO) application of Bellen Chemistry Co., Ltd. has been approved by the Listing Committee. The company is planning to be listed on the GEM. The lead sponsor institution for this issuance is CITIC Securities Co., Ltd.

Since 2010, Bellen Chemistry has been providing chemistry CRO/CDMO services as an integrated Contract Chemistry Service Organization(CCSO). With years of accumulated technical advantages and experiences in chemical synthesis of small molecule compounds, Bellen has built a one-stop shop chemistry service platform, supporting global pharmaceutical companies, biotech innovators and new drug development institutions for their research programs from discovery to commercial stage through comprehensive chemistry solutions.

The company’s business started from design and development of novel heterocycles and gradually formed a complete and a variety of product list, and established a core technology system represented by special reaction technology platform, new technology application platform, catalyst screening platform and new molecule design and route development platform, which laid a solid foundation for the company to establish an integrated chemistry service platform for small molecule new drug research and development.

We are committed to turning the company into a benchmark in its niche area by providing specialized chemistry solutions that empowers global innovators for new drug development, helping them to shorten research time and reduce costs, thereby improving efficiency and ultimately achieving early launch of new drugs for the benefit of patients around the world.

We adhere to the people-oriented development strategy and constantly increase investment in innovation and make every effort to promote talent growth. Our R&D, production, sales and operation team are based globally and at present, Bellen has nearly 1,000 employees worldwide, of which technical team accounts for more than 50%.

Bellen has been dedicated and persistent in what we do over a decade. We have built strong technical capabilities and robust quality and EHS management system. Going forward, we will continue investment in innovation, talent acquisition, capability and capacity to enable an integrated one-stop shop chemistry service platform by providing to our global partners with more open, complete, reliable, and efficient research and manufacturing solutions.